Anti-atherosclerotic effects of statins: Lessons from prevention trials

European Journal of Preventive Cardiology

Volumn 10, Issue 3, 2003, Pages 155-159

  Ganesh, Santhi K ^a   Nass, Caitlin M ^b   Blumenthal, Roger S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

atherosclerosis; cholesterol; lipids; prevention

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; COLESTYRAMINE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; MEVINOLIN; NICOTINIC ACID;

ANGINA PECTORIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; HEART INFARCTION; HUMAN; MORTALITY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS; AGE DISTRIBUTION; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATALITY; HIGH RISK PATIENT; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SEX RATIO;

ARTERIOSCLEROSIS; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0038348432     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000072574.13775.6d     Document Type: Article

References (35)

1. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389. This trial proved that statin therapy decreased total mortality in a secondary prevention setting.
2. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357. LIPID also showed a decrease in total mortality in patients with vascular disease treated with statins.
3. Cholesterol and Recurrent Events Trial Investigators Sacks FM, Pfeffer MA, Moye LA, Brown L, Rouleau JL, Hartley LH, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–1009. Pravastatin decreased CAD events in post-MI patients with average cholesterol levels.
4. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998; 97: 1446–1452.
5. CARE investigators Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998; 32: 40–46. Women derived an even greater risk reduction than men from pravastatin therapy in this trial.
6. West of Scotland Coronary Prevention Study Group Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301–1307.
7. AFCAPS/TexCAPS Research Group Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622. Patients with a sub-optimal total cholesterol/HDL ratio benefit from statin therapy.
8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2485–2497.
9. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–381.
10. Lipid Research Clinics Program The Lipid Research Clinics Coronary Primary Prevention Trial results: Reduction in the incidence of coronary artery disease. JAMA 1984; 251: 351–364.
11. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–1245.
12. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass graft. N Engl J Med 1997; 336: 153–162. Aggressive lipid lowering is warranted in post-CABG patients.
13. Popma J, Sawyer M, Selwyn A, Kinlay S. Lipid lowering therapy after revascularization: The interventionalist's perspective. Am J Cardiol 2000; 86: 18H–28H. All patients who undergo revascularization should receive aggressive lipid management.
14. Schwartz GG, Oliver MR, Ezekowitz M, Ganz P, Waters D, Kane J, et al. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave myocardial infarction. Am J Cardiol 1998; 81: 578–581.
15. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1–10. This review summarizes the non-lipid effects of statins.
16. Koh KK. Effects of statin on vascular wall: Vasomotor function, inflammation and plaque stability. Cardiovascular Research 2000; 47: 648–657.
17. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (Reduction of Cholesterol in ischemia and Function of the Endothelium) Trial. Circulation 1999; 99: 3227–3233.
18. Cannon R. Cardiovascular benefit of cholesterol-lowering therapy. Does improved endothelial vasodilator function matter? Circulation 2000; 102: 820–822.
19. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. For the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613. Combined, continuous HRT did not reduce CAD events in the secondary prevention setting.
20. Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000; 102: 846–851.
21. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–1298.
22. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278–286. The benefits of fluvastatin were most prominent in patients with HDL #38;#60;35 mg/dL.
23. Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. Eur Heart J 1997; 18: 226–234.
24. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. For the PLAC-I Investigators. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133–1139.
25. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995; 91: 2528–2540.
26. MAAS Investigators Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–638.
27. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993; 119: 969–976.
28. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994; 89: 959–968.
29. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid-lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781–1791.
30. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996; 348: 1079–1082.
31. Aengevaeren W, Uijen G, Jukema W, Bruschke A, Van der Werf T. Functional evaluation of lipid-lowering therapy by pravastatin in the regression growth evaluation statin study (REGRESS). Circulation 1997; 96(2): 429–435.
32. Forrester JS. Role of plaque rupture in acute coronary syndromes. Am J Cardiol 2000; 86(Suppl): 15J–23J.
33. Nissen SE. Rationale for post-intervention continuum of care: Insights from intravascular ultrasound. Am J Cardiol 2000; 86(Suppl): 12H–17H. IVUS is a very sensitive way to assess changes in vessel walls.
34. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, Ellis SG. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691–696.
35. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003; 107: 1750–1756.